Edition:
India

Sangamo Therapeutics Inc (SGMO.OQ)

SGMO.OQ on NASDAQ Stock Exchange Global Select Market

16.12USD
1:30am IST
Change (% chg)

$-1.92 (-10.66%)
Prev Close
$18.05
Open
$18.10
Day's High
$18.15
Day's Low
$16.00
Volume
827,152
Avg. Vol
539,363
52-wk High
$27.50
52-wk Low
$7.38

Select another date:

Tue, May 8 2018

BRIEF-Sangamo Therapeutics Reports Q1 Loss Per Share Of $0.23

* SANGAMO THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Sangamo Therapeutics Prices Public Offering Of Common Stock

* SANGAMO THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BRIEF-Sangamo Therapeutics Proposes Public Offering Of Common Stock

* SANGAMO THERAPEUTICS ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BRIEF-Sangamo Therapeutics Files For Potential Mixed Shelf Offering

* SANGAMO THERAPEUTICS INC FILES FOR POTENTIAL MIXED SHELF OFFERING; SIZE NOT DISCLOSED- SEC FILING Source text (https://bit.ly/2vH7vVF) Further company coverage:

BRIEF-Sangamo Therapeutics Says Co Announced A Data Security Incident Involving Compromise Of A Senior Executive's Company Email Account

* SANGAMO THERAPEUTICS SAYS ON APRIL 17, CO ANNOUNCED A DATA SECURITY INCIDENT INVOLVING COMPROMISE OF A SENIOR EXECUTIVE'S COMPANY EMAIL ACCOUNT

Sangamo in $3 billion gene-editing deal with Gilead

U.S. drugmaker Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology to develop cancer treatments in a deal potentially worth about $3 billion to Sangamo, the companies said on Thursday.

Gilead signs $3 bln licensing deal for Sangamo's gene-editing platform

Feb 22 Gilead Sciences Inc will use Sangamo Therapeutics Inc's gene-editing technology platform to develop cancer treatments, in a collaboration deal worth more than $3 billion, the two companies said on Thursday.

BRIEF-Sangamo Therapeutics Q4 Loss Per Share $0.15

* SANGAMO THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

BRIEF-Kite And Sangamo Therapeutics Announce Collaboration To Develop Cell Therapies For Treatment Of Cancer

* KITE, A GILEAD COMPANY, AND SANGAMO THERAPEUTICS ANNOUNCE COLLABORATION TO DEVELOP NEXT-GENERATION ENGINEERED CELL THERAPIES FOR THE TREATMENT OF CANCER

BRIEF-Sangamo Therapeutics Appoints Heather Turner As Senior Vice President

* SANGAMO THERAPEUTICS ANNOUNCES APPOINTMENT OF HEATHER D. TURNER AS SENIOR VICE PRESIDENT AND GENERAL COUNSEL Source text for Eikon: Further company coverage:

Select another date: